| Drug General Information |
| Drug ID |
D0U3DP
|
| Former ID |
DIB015885
|
| Drug Name |
VS-5584
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1],
[2]
|
|---|
| Company |
Verastem
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H22N8O
|
| InChI |
InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20)
|
| InChIKey |
QYBGBLQCOOISAR-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
99376660, 120919500, 163621035, 163686364, 169548936, 184824937, 208265527, 223382832, 223702838, 224593968, 226848955, 241383889, 245285867, 249683938, 250225766, 252074133, 252166594, 252216594, 252444830, 252473852
|
| Target and Pathway |
| Target(s) |
Serine/threonine-protein kinase mTOR |
Target Info |
Modulator |
[1]
|
|---|
| Phosphoinositide 3 kinase |
Target Info |
Modulator |
[1]
|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
HIF-1 signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Insulin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Acute myeloid leukemia
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa00562:Inositol phosphate metabolism
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
FoxO signaling pathway
|
|
Phosphatidylinositol signaling system
|
|
Sphingolipid signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
Jak-STAT signaling pathway
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Regulation of actin cytoskeleton
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Aldosterone-regulated sodium reabsorption
|
|
Carbohydrate digestion and absorption
|
|
Bacterial invasion of epithelial cells
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Melanoma
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancer
|
|
Choline metabolism in cancer
|
|
PANTHER Pathway
|
Hypoxia response via HIF activation
|
|
Interleukin signaling pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
IL12-mediated signaling events
|
|
CDC42 signaling events
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
mTOR signaling pathway
|
|
CXCR4-mediated signaling events
|
|
EGFR-dependent Endothelin signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IFN-gamma pathway
|
|
ErbB1 downstream signaling
|
|
ErbB2/ErbB3 signaling events
|
|
CXCR3-mediated signaling events
|
|
Class I PI3K signaling events mediated by Akt
|
|
PathWhiz Pathway
|
Leucine Stimulation on Insulin SignalingPW000143:Inositol Metabolism
|
|
Phosphatidylinositol Phosphate Metabolism
|
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
PIP3 activates AKT signaling
|
|
Macroautophagy
|
|
mTORC1-mediated signalling
|
|
HSF1-dependent transactivation
|
|
CD28 dependent PI3K/Akt signaling
|
|
VEGFR2 mediated vascular permeability
|
|
TP53 Regulates Metabolic Genes
|
|
Constitutive Signaling by AKT1 E17K in CancerR-HSA-109704:PI3K Cascade
|
|
GPVI-mediated activation cascade
|
|
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
|
PI3K events in ERBB4 signaling
|
|
GAB1 signalosome
|
|
PI3K events in ERBB2 signaling
|
|
PI3K/AKT activation
|
|
Role of phospholipids in phagocytosis
|
|
Tie2 Signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
DAP12 signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
Nephrin interactions
|
|
Costimulation by the CD28 family
|
|
G beta:gamma signalling through PI3Kgamma
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling events
|
|
VEGFA-VEGFR2 Pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Constitutive Signaling by EGFRvIII
|
|
PI-3K cascade:FGFR1
|
|
PI-3K cascade:FGFR2
|
|
PI-3K cascade:FGFR3
|
|
PI-3K cascade:FGFR4
|
|
Interleukin receptor SHC signaling
|
|
Regulation of signaling by CBL
|
|
WikiPathways
|
ErbB Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Interferon type I signaling pathways
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
Wnt Signaling Pathway Netpath
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Cardiac Hypertrophic Response
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
PIP3 activates AKT signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
TSLP Signaling Pathway
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Integrated Breast Cancer Pathway
|
|
SREBP signalling
|
|
Signaling by Insulin receptor
|
|
Costimulation by the CD28 family
|
|
Type II diabetes mellitus
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
TOR Signaling
|
|
AMPK SignalingWP75:Toll-like receptor signaling pathway
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
IL-4 Signaling Pathway
|
|
Copper homeostasis
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Transcriptional activation by NRF2
|
|
IL1 and megakaryotyces in obesity
|
|
Signaling by ERBB4
|
|
Signaling by ERBB2
|
|
Fc epsilon receptor (FCERI) signaling
|
|
PI Metabolism
|
|
Interleukin-2 signaling
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
Signaling by SCF-KIT
|
|
DAP12 interactions
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Integrated Pancreatic Cancer Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Regulation of Microtubule Cytoskeleton
|
|
TCR signaling
|
|
Signaling by PDGF
|
|
Signaling by FGFR
|
|
Signaling by EGFR
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Nephrin interactions
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
GPVI-mediated activation cascade
|
|
GPCR downstream signaling
|
|
Cell surface interactions at the vascular wall
|
|
Angiogenesis
|
|
Regulation of toll-like receptor signaling pathway
|
|
AMPK Signaling
|
| References |
| REF 1 | VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8382). |
|---|
